{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T05:15:35Z","timestamp":1735362935909,"version":"3.32.0"},"reference-count":162,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"McLaughlin Scholarship from Laval University"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Neurotherapeutics"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1080\/14737175.2024.2376840","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:10:00Z","timestamp":1720530600000},"page":"897-912","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["The importance of synthetic pharmacotherapy for recessive cerebellar ataxias"],"prefix":"10.1080","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8615-4390","authenticated-orcid":false,"given":"Marie","family":"Beaudin","sequence":"first","affiliation":[{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine, Stanford, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Dupre","sequence":"additional","affiliation":[{"name":"Neuroscience axis, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, QC, Canada"},{"name":"Department of Medicine, Faculty of Medicine, Universit\u00e9 Laval, Quebec, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Manto","sequence":"additional","affiliation":[{"name":"Service des Neurosciences, Universit\u00e9 de Mons, Mons, Belgique"},{"name":"Unit\u00e9 des Ataxies C\u00e9r\u00e9belleuses, Service de Neurologie, CHU-Charleroi, Charleroi, Belgique"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40673-015-0023-1"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-019-01052-2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000358801"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-331490"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0372-4"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2023.05.005"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207406"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.12.002"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad157"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5254.1423"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.332"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00634-9"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01475-9"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26382"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199902)45:2<200:aid-ana10>3.0.co;2-u"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104606"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.03.019"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063958"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23789"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21052"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004253"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2012.4537"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1042\/NS20200093"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14047853"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101483"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31827e5762"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0326-3"},{"key":"e_1_3_4_29_1","unstructured":"Agency EM. Skyclarys (Omaveloxolone). [cited 2024 Apr 30]. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyclarys"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00188"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25934"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.660"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29286"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2173063"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S136992"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2018-0013"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.09.007"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000200034"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00495-1"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7719-2"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-11-0148"},{"key":"e_1_3_4_42_1","unstructured":"Murdoch Childrens Research I. Micronised resveratrol as a treatment for Friedreich Ataxia. [cited 2024 May 27]. Available online https:\/\/ClinicalTrials.gov\/show\/NCT03933163"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41120-022-00058-1"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.755"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10320-2"},{"key":"e_1_3_4_46_1","unstructured":"Children\u2019s Hospital of Philadelphia. FRDA Investigator Initiated Study (IIS) With Elamipretide (ELViS-FA). Clinicaltrials.gov. 2024 [cited 2024 Jan 16]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05168774"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2024.101846"},{"key":"e_1_3_4_48_1","unstructured":"Children\u2019s Hospital of Philadelphia. NAD+ and Exercise in FA (ExRx in FA). Clinicaltrials.gov. 2024 [cited 2024 Apr 02]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04192136"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93885"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13668-023-00475-y"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad027"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27604"},{"key":"e_1_3_4_54_1","unstructured":"IRCCS Eugenio Medea. Safety and Efficacy of Etravirine in Friedreich Ataxia Patients (FAEST1). Clinicaltrials.gov. 2023 [cited 2024 Jan 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04273165"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217776"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx167"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddaa282"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1260977"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr554"},{"key":"e_1_3_4_60_1","unstructured":"Larimar Therapeutics Inc. A Double-Blind Placebo-Controlled Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich\u2019s Ataxia. 2024 [cited 2024 Mar 01]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT05579691"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2012.07.005"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3510"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.363"},{"key":"e_1_3_4_64_1","unstructured":"Lexeo Therapeutics. Gene therapy for cardiomyopathy associated with Friedreich\u2019s Ataxia. Clinicaltrials.gov. 2024 [cited 2024 Jan 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05445323"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6414"},{"key":"e_1_3_4_66_1","unstructured":"Design Therapeutics Inc. Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia. Clinicaltrials.gov. 2024 [cited 2024 Mar 01]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05573698"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8244-7"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.006"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2017.0703"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10606"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115472"},{"key":"e_1_3_4_73_1","volume-title":"Proceedings of the Muscular Dystrophy Association (MDA) 2024 Clinical and scientific conference","author":"D L","year":"2024","unstructured":"D L. Safety and efficacy of vatiquinone treatment in friedreich ataxia patients from MOVE -FA: a phase 3, double-blind, placebo-controlled trial. In: Proceedings of the Muscular Dystrophy Association (MDA) 2024 Clinical and scientific conference; Orlando, FL; 2024."},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.02.013"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.007"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.68"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.08.018"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.02.002"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.148"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27606"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29819"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.01.010"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24248"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70220-X"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.168"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007791.pub4"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds110"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.731"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0b013e3181910074"},{"key":"e_1_3_4_93_1","unstructured":"University of South Florida. Pilot Study of Varenicline (Chantix\u00ae) in the Treatment of Friedreich\u2019s Ataxia. Clinicaltrials.gov. 2012 [cited 2024 May 30]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00803868"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27319"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9091969"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06277-0"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2249399"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300338"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.03.020"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411421"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-5793(00)01422-8"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1005"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28788"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.10.1479"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25126"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2019.05.006"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-9-5"},{"key":"e_1_3_4_109_1","unstructured":"Quince Therapeutics S.p.A. Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients (ATTeST). Clinicaltrials.gov. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02770807"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/dmcn.15476"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101354"},{"key":"e_1_3_4_113_1","volume-title":"GeneReviews\u00ae [Internet]","author":"Veenhuis S","year":"1993","unstructured":"Veenhuis S, van Os N, Weemaes C, et al. Ataxia-Telangiectasia. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington; 1993\u20132024 [cited 2024 Mar 01].https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK26468\/"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a55fa2"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-019-04399-3"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073812441999"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00201-X"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12081040"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0953-816x.2000.01447.x"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa148"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310151"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201660"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.35841"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738211028394"},{"key":"e_1_3_4_125_1","unstructured":"IntraBio Inc. N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T). Clinicaltrials.gov. 2024 [cited 2024 Feb 27]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03759678"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-05009-3"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-013-9665-4"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.298"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2001.00273.x"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25751"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2019.100548"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx231"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40673-018-0091-0"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1252-9"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.06.008"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2015.06.007"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184022"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aws122"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2016.05.021"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0913-4"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70194-1"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.161059"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.11.007"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rceng.2022.02.008"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107656"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810895106"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M000257"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-017-2833-9"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31465-4"},{"key":"e_1_3_4_150_1","unstructured":"Mandos LLC. Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System. Clinicaltrials.gov. 2021 [cited 2024 May 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03643562"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2023.100988"},{"key":"e_1_3_4_152_1","unstructured":"Cyclo Therapeutics Inc. Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1 (TransportNPC). Clinicaltrials.gov. 2024 [cited 2024 May 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04860960"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2021.11.176"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948143"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031471"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-15070-8_83"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1270296"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006210"},{"key":"e_1_3_4_160_1","unstructured":"Borroni B; Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia. Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia. Clinicaltrials.gov. 2021 [cited 2024 Jan 15]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04153110"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-011-0316-8"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2276758"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30287-3"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51886"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000371"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12311-023-01621-6"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26200"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-24345-5_29"},{"key":"e_1_3_4_169_1","volume-title":"Proceedings of the Muscular Dystrophy Association (MDA) 2024 Clinical and Scientific Conference","author":"P S","year":"2024","unstructured":"P S. Fordadistrogene movaparvovec for Duchenne muscular dystrophy: 3 - year functional outcomes and changes in thigh and upper-limb muscle volume. In: Proceedings of the Muscular Dystrophy Association (MDA) 2024 Clinical and Scientific Conference; Orlando, FL; 2024 Mar 6."},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26714"}],"container-title":["Expert Review of Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737175.2024.2376840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T10:22:21Z","timestamp":1735294941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737175.2024.2376840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":162,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1080\/14737175.2024.2376840"],"URL":"https:\/\/doi.org\/10.1080\/14737175.2024.2376840","relation":{},"ISSN":["1473-7175","1744-8360"],"issn-type":[{"type":"print","value":"1473-7175"},{"type":"electronic","value":"1744-8360"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iern20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}